Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings
- 1 March 2012
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 16 (3) , 193-197
Abstract
Aims: Pharmacogenetic (PGx) tests are intended to improve therapeutic outcomes through predicting a patient's likelihood to respond to or experience an adverse effect from a specific treatment. In addition, PGx testing may also generate ancillary, or incidental, disease information unrelated to the purpose for which the test was ordered. To assess public attitudes toward PGx testing, ancillary disease risk information and related clinical issues, we conducted a series of focus groups. Results: Forty-five individuals recruited from Durham, NC, participated in four focus groups. Overall, participants were enthusiastic about PGx testing, though expressed concerns about privacy, confidentiality, and psychological harms associated with ancillary information. Focus group participants believed that physicians had a responsibility to disclose ancillary risk information, but were concerned about managing and coping with unexpected disease risk information. Conclusion: We find that participants welcomed the integration of PGx testing into therapeutic decision-making. Public concerns about PGx testing and ancillary information specifically centered on personal implications of learning such additional information, suggesting that patient–provider discussion of the benefits and risks of testing will be necessary until public familiarity with these tests increases.Keywords
This publication has 23 references indexed in Scilit:
- Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditionsGenetics in Medicine, 2011
- Differences Between African American and White Research Volunteers in Their Attitudes, Beliefs and Knowledge Regarding Genetic Testing for Alzheimer's DiseaseJournal of Genetic Counseling, 2011
- Survey of US public attitudes toward pharmacogenetic testingThe Pharmacogenomics Journal, 2011
- Pharmacogenetic testing: not as simple as it seemsGenetics in Medicine, 2008
- Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescriptionJournal of Clinical Pharmacy and Therapeutics, 2007
- Racial Differences in the Use of BRCA1/2 Testing Among Women With a Family History of Breast or Ovarian CancerJAMA, 2005
- A lay prescription for tailor-made drugs—focus group reflections on pharmacogenomicsHealth Policy, 2005
- Evaluating Direct-to-Consumer Marketing of Race-Based Pharmacogenomics: A Focus Group Study of Public Understandings of Applied Genomic MedicationJournal of Health Communication, 2004
- Informed lay preferences for delivery of racially varied pharmacogenomicsGenetics in Medicine, 2003
- Attitudinal barriers to delivery of race-targeted pharmacogenomics among informed lay personsGenetics in Medicine, 2003